Visual Impairment Clinical Trial
— SPECTRUM-USOfficial title:
Real-World Patient Characteristics, Treatment Patterns, and Outcomes Among Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) Treated With Aflibercept 8 mg in the United States
The purpose of this research study is to observe the patient's clinical care and how EYLEA® HD is used as a treatment in real-world settings. Patients are asked to join the study because they have either neovascular age-related macular degeneration (nAMD/wet age-related macular degeneration [AMD]) or diabetic macular edema (DME). Patients cannot have used EYLEA® HD in the past and the doctor must be planning to treat nAMD or DME with a new prescription of EYLEA® HD (aflibercept 8 mg).
Status | Not yet recruiting |
Enrollment | 800 |
Est. completion date | November 13, 2028 |
Est. primary completion date | November 13, 2027 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Key Inclusion Criteria for Patients with nAMD: 1. Any patient aged at least 50 years at the time of enrollment 2. Diagnosis of nAMD (per physician) 3. Previously treated patient cohort, patients that had treatment with any ocular intervention for nAMD in the study eye at any time before starting aflibercept 8 mg, as defined in the protocol 4. For treatment-naïve patient cohort, patients never receiving previous treatment in the study eye for nAMD, as defined in the protocol 5. Initiating treatment with aflibercept 8 mg for nAMD Key Inclusion Criteria for Patients with DME: 1. Any patient aged at least 18 years at the time of enrollment 2. Macular edema associated with DME (per physician) 3. Diagnosis of diabetes mellitus type 1 or type 2 4. For previously treated patient cohort, treatment with another intravitreal (IVT) anti-VEGF agent(s) or IVT steroids, or surgery/laser for DME in the study eye at any time before starting aflibercept 8 mg, as described in the protocol 5. For treatment-naïve patient cohort, patients never previously treated with IVT agents or surgery/laser in the study eye for DME 6. Initiating treatment with aflibercept 8 mg for DME Key Exclusion Criteria for Patients with nAMD 1. Macular edema/hemorrhage/choroidal neovascularization due to any other cause besides nAMD 2. Any systemic or ocular condition that would prevent any improvement of VA in the study eye (eg, permanent visual impairment or blindness from any cause) 3. Any patients that have been treated with photodynamic therapy 4. Treatment with aflibercept 8 mg prior to baseline Key Exclusion Criteria for Patients with DME: 1. Macular edema due to any other cause besides DME 2. Any systemic or ocular condition that would prevent any improvement of visual acuity in the study eye (eg, permanent visual impairment or blindness from any cause) 3. Treatment with aflibercept 8 mg prior to baseline NOTE: Other Protocol-Defined Inclusion / Exclusion Criteria Apply |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Regeneron Pharmaceuticals |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Mean prior treatment interval during the one-year period before study enrollment compared to the last assigned treatment interval during the study | Previously Treated Patient Cohorts:
Reported among the subsets of patients (nAMD and DME) treated at dosing intervals of = 8 weeks for = 6 months prior to enrollment |
Up to 12 Months | |
Primary | Change in visual acuity (VA) (Early Treatment Diabetic Retinopathy study [ETDRS]) letters) | Treatment-Naïve Patient Cohorts | Baseline up to 12 Months | |
Secondary | Change in VA (ETDRS letters) | Baseline up to 24 Months | ||
Secondary | Categorical gains of =5 ETDRS letters | Up to 24 Months | ||
Secondary | Categorical gains of =10 ETDRS letters | Up to 24 Months | ||
Secondary | Categorical gains of =15 ETDRS letters | Up to 24 Months | ||
Secondary | Categorical losses of =5 ETDRS letters | Up to 24 Months | ||
Secondary | Categorical losses of =10 ETDRS letters | Up to 24 Months | ||
Secondary | Categorical losses of =15 ETDRS letters | Up to 24 Months | ||
Secondary | Proportion of patients achieving 20/40 Snellen equivalent or better | Up to 24 Months | ||
Secondary | Change in Central subfield thickness (CST) | Baseline up to 24 Months | ||
Secondary | Description of demographics | Standard and clinical characteristics such as age, sex and race/ethnicity | At Baseline | |
Secondary | Descriptions of study eye characteristics | Study eye characteristics include ocular history, medical history (duration of nAMD or DME), prior and concomitant medication history, prior and concomitant ocular surgeries | At Baseline | |
Secondary | Treatment interval | Up to 24 Months | ||
Secondary | Missed and unscheduled visits | Up to 24 Months | ||
Secondary | Frequency of ocular adverse events (AEs) | Up to 24 Months | ||
Secondary | Frequency of non-ocular adverse events (AEs) | Up to 24 Months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06000865 -
Glaucoma Rehabilitation With Action viDeo Games and Exercise - GRADE
|
N/A | |
Recruiting |
NCT05619432 -
Re:Garde Program - Training and Maintaining Visual Perception in Older Adults
|
N/A | |
Completed |
NCT03670303 -
Trial of an Educational Intervention to Promote Spectacle Use Among Secondary School Children in Islamabad, Pakistan
|
N/A | |
Completed |
NCT02896738 -
MRI Screening for Auditory Pathway Malformations in Visually Impaired Children
|
||
Completed |
NCT01822717 -
Nonvisual Foot Inspection for People With Visual Imapirment
|
N/A | |
Completed |
NCT03865134 -
Evaluation of Visual - Motor Development in Children With Retinopathy of Prematurity
|
||
Active, not recruiting |
NCT04198350 -
Pancreatic Islet Transplantation to the Anterior Chamber of the Eye
|
N/A | |
Recruiting |
NCT05220449 -
Re-Orchestration of Interregional Oscillatory Activity to Promote Visual Recovery
|
N/A | |
Completed |
NCT04190147 -
Eye and Growth in Adolescents Born Moderate-to-late Preterm
|
||
Completed |
NCT05135195 -
A Virtual Reality Platform Simulating Visual Impairment for Testing of Electronic Travel Aids and Performing Orientation and Mobility Training
|
N/A | |
Recruiting |
NCT05199363 -
Pediatric Patient Experience on a Diagnostic Path
|
N/A | |
Active, not recruiting |
NCT03767803 -
Collection of Whole Blood Samples for the Evaluation of Preeclampsia (Pre-E) Biomarkers From Pregnant Women
|
||
Recruiting |
NCT03571217 -
Shanghai Beixinjing Diabetic Eyes Study
|
||
Not yet recruiting |
NCT03726606 -
A Comparison of the Visual Performance of Trifocal Versus Extended Depth of Focus Intraocular Lenses
|
N/A | |
Completed |
NCT02259088 -
A 12-month, Randomized, Efficacy and Safety Study of 0.5 mg Ranibizumab vs Laser in Chinese Diabetic Macular Edema (DME) Patients
|
Phase 3 | |
Completed |
NCT06197607 -
Effect of Hand Exercises on Hand Grip Strength and Manual Ability in Children With Visual Impairment
|
N/A | |
Withdrawn |
NCT04579653 -
Pupillometry and Locus Coeruleus Activation (PuLCA)
|
N/A | |
Recruiting |
NCT05844982 -
Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of VA Loss Due to Radiation Retinopathy
|
Phase 3 | |
Recruiting |
NCT02258113 -
Measuring of Neuro-visual Functionality With Ocusweep
|
N/A | |
Completed |
NCT02607384 -
The Baltimore Reading and Eye Disease Study
|
N/A |